Ekso Bionics Q2 revenue misses estimates, net loss widens

Chronoscale

28/07/2025 21:15

Overview

Ekso Bionics Q2 revenue of $2.1 mln missed analyst expectations

Company reported net loss of $2.7 mln for Q2 2025

Personal Health product sales grew over 50% yr/yr in H1 2025

Outlook

Ekso anticipates recovery in H2 driven by Personal Health demand

Ekso sees over 50% growth in Personal Health products Y-o-Y

Company aims to meet anticipated Enterprise Health customer demand

Result Drivers

ENTERPRISE HEALTH SALES - Revenue decline attributed to short-term delays in completing multi-device Enterprise Health sales, per CEO Scott Davis

PERSONAL HEALTH GROWTH - Personal Health product sales grew over 50% year-over-year in H1 2025

GROSS MARGIN PRESSURE - Gross margin decreased due to fixed costs and increased shipping costs, partially offset by improved service margins

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$2.06 mln
$4.31 mln (2 Analysts)
Q2 EPS
-$1.24
Q2 Net Ioss
$2.71 mln
Q2 Operating Expenses
$4.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Ekso Bionics Holdings Inc is $37.50, about 87.1% above its July 25 closing price of $4.82

Press Release: ID:nGNX6yKn6m

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)